A Phase 2 interventional study of MC2-01 cream in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Terminated at 2 sites in 2 countries. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by MC2 Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 43rd largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 2, and was the 37th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
MC2 Therapeutics is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
MC2 Therapeutics has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive psoriasis vulgaris.
The MC2-01 cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on with daily routines. In this trial, subjects who fulfil all inclusion and exclusion criteria are enrolled in the trial and will apply one dose of trial medication topically once daily for 8 weeks. The purpose of the trial, is to determine the and pharmacokinetic parameters of MC2-01 cream in adolescent subjects under maximum use conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
Drug: MC2-01 cream
Drug pages: Calcipotriene · Betamethasone dipropionate
MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 4
Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL
Time frame: Week 4
Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 8
Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL
Time frame: Week 8
Change in S-Calcium Metabolism at Week 4
Change from Baseline to Week 4 in albumin-corrected S-calcium
Time frame: Week 4
Change in S-Calcium Metabolism at Week 8
Change from Baseline to Week 8 in albumin-corrected S-calcium
Time frame: Week 8
Change in U-Calcium Metabolism at Week 4
Change from Baseline to Week 4 in Urinary Calcium/Creatinine ratio (mol/mol)
Time frame: Week 4
Change in U-Calcium Metabolism at Week 8
Change from Baseline to Week 8 in Urinary Calcium/Creatinine ratio (mol/mol)
Time frame: Week 8
The Maximum Plasma Concentration [Cmax] of Betamethasone 17-propionate at Week 4
The Maximum Plasma Concentration \[Cmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.
Time frame: Week 4
Time to Maximum Plasma Drug Concentration [Tmax] of Betamethasone 17-propionate at Week 4
Time to maximum plasma drug concentration \[Tmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.
Time frame: Week 4
| Milestone | MC2-01 Cream |
|---|---|
| Started | 7 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Protocol violation | 1 |
Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL
| Participants | MC2-01 Cream |
|---|---|
| Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 4 | 0 |
Adrenal function will be assessed in a challenge test with an intravenous dose of cosyntropin. Measurement of serum cortisol levels pre- and post- stimulation is an accepted standard method used to evaluate adrenal suppression. The test consists of an initial blood sampling. Following the blood sample, an intravenous bolus injection of 0.25 mg cosyntropin is given. The serum cortisol concentration 30 min. after will reflect stimulation of the adrenal glands induced by cosyntropin. HPA axis suppression is define as serum cortisol below 18 µg/dL
| Participants | MC2-01 Cream |
|---|---|
| Number of Participants With HPA (Hypothalamic-pituitary-adrenal) Axis Suppression at Week 8 | 0 |
Change from Baseline to Week 4 in albumin-corrected S-calcium
| mmol/L | MC2-01 Cream |
|---|---|
| Change in S-Calcium Metabolism at Week 4 | -0.037 ± 0.084 |
Change from Baseline to Week 8 in albumin-corrected S-calcium
| mmol/L | MC2-01 Cream |
|---|---|
| Change in S-Calcium Metabolism at Week 8 | -0.027 ± 0.060 |
Change from Baseline to Week 4 in Urinary Calcium/Creatinine ratio (mol/mol)
| mol/mol | MC2-01 Cream |
|---|---|
| Change in U-Calcium Metabolism at Week 4 | 0.115 ± 0.426 |
Change from Baseline to Week 8 in Urinary Calcium/Creatinine ratio (mol/mol)
| mol/mol | MC2-01 Cream |
|---|---|
| Change in U-Calcium Metabolism at Week 8 | 0.058 ± 0,186 |
The Maximum Plasma Concentration \[Cmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.
| pg/mL | MC2-01 Cream |
|---|---|
| The Maximum Plasma Concentration [Cmax] of Betamethasone 17-propionate at Week 4 | 37.53 ± 22.82 |
Time to maximum plasma drug concentration \[Tmax\] of the metabolite of BDP, betamethasone 17-propionate measured at Week 4.
| Hours | MC2-01 Cream |
|---|---|
| Time to Maximum Plasma Drug Concentration [Tmax] of Betamethasone 17-propionate at Week 4 | 2.333 ± 1.155 |
Collected over AEs were collected/assessed from the time of the signature of the informed consent form by the participant and until the final follow-up visit has occurred, i.e. up to in total up to 18 weeks, including a screening period of up to 6 weeks, a treatment period of 8 weeks and a follow-up period of 4 weeks. AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition of the participant was stable.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MC2-01 Cream | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Event | MC2-01 Cream |
|---|---|
| NasopharyngitisInfections and infestations | 1/7 |
| TonsillitisInfections and infestations | 1/7 |
| DysuriaRenal and urinary disorders | 1/7 |
| AcneSkin and subcutaneous tissue disorders | 1/7 |
| Age, Continuous(years) | MC2-01 Cream |
|---|---|
| Mean | 14.7 ± 1.4 |
| Sex: Female, Male(Participants) | MC2-01 Cream |
|---|---|
| Female | 3 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | MC2-01 Cream |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | MC2-01 Cream |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | MC2-01 Cream |
|---|---|
| Czechia | 5 |
| Germany | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Dec 2020, 23 months.
Results were first posted in Feb 2021, 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate
MC2 Therapeutics